News coverage about Thoratec (NASDAQ:THOR) has trended somewhat negative this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Thoratec earned a news sentiment score of -0.12 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 46.0390641515716 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Thoratec (NASDAQ:THOR) remained flat at $63.50 during midday trading on Friday. The firm has a 50 day moving average price of $63.03 and a 200-day moving average price of $51.62. Thoratec has a 12 month low of $25.04 and a 12 month high of $63.51.
Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company’s products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD).
What are top analysts saying about Thoratec Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thoratec Co. and related companies.